Tic

Neupulse Secures Funding to Advance World’s First Wearable Device to Tackle Tourettes Syndrome

Retrieved on: 
Monday, March 18, 2024
Wearables, Mobile Technology, Technology, Medical Devices, Neurology, Health Technology, Biotechnology, Hardware, Health, General Health, Tic, University, Education, TS, Eos, Tourette syndrome, Quality of life, Pain, Median nerve, Multimedia, Wrist, Work, Social integration, Pharmaceutical industry

Neupulse has secured funding to advance the world’s first wearable device aimed at tackling Tourettes Syndrome (TS) and other tic disorders towards commercialization.

Key Points: 
  • Neupulse has secured funding to advance the world’s first wearable device aimed at tackling Tourettes Syndrome (TS) and other tic disorders towards commercialization.
  • Clinical trials in 2023 showed the Neupulse device can reduce tics by over 25 percentile.
  • Tourettes Syndrome is a neurological condition characterized by involuntary, repetitive movements and vocalizations known as tics.
  • Our device is an alternative to the current provision of treatment for TS, which is centred around medication and cognitive behaviour therapy.

SciSparc Aims to Change Tourette Syndrome Treatments; Will Start a Phase IIb Trial with its Innovative Pharma-Grade THC-Based Medication

Retrieved on: 
Friday, November 10, 2023
Ministry, Safety, TS, Food, Yale University, Disorder, THC, Clinical trial, Medical device, Patient, IIA, FDA, Movement, Hannover Medical School, Cannabinoid, Tourette syndrome, Learning, Central nervous system, Tic, TEL, PEA, Pharmaceutical industry, Dronabinol, Health

TEL AVIV, Israel, Nov. 10, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced the initiation of its Phase IIb clinical trial treating patients suffering from Tourette Syndrome (TS) with its SCI-110, proprietary drug candidate.

Key Points: 
  • SciSparc initiated the trial at the Tel Aviv Sourasky Medical Center in Israel (Sourasky) and is expected to proceed with its U.S. and Germany-based medical sites.
  • TS is a movement and neurobehavioral disorder characterized by motor and vocal tics and is highly linked with co-morbidities.
  • The patients will be randomized at a 1:1 ratio to receive either SCI-110 or a SCI-110-matched placebo.
  • In addition, the medication was generally well-tolerated by subjects and 12 out of the 16 subjects elected to continue into a 24-week extension phase of the trial.

Heat And Energy Recovery Ventilation System Market size to increase by USD 1.77 billion during 2023-2028, Rising demand for heat and energy recovery ventilation systems due to awareness of indoor air quality to drive the growth - Technavio

Retrieved on: 
Friday, December 15, 2023
Transfer, Electronics, Element, Cross, Trane Technologies, Tic, Growth, HVAC, FREE, Johnson Controls, Daikin, Internet of things, Lennox International, Filter (signal processing), Cabinet, Education minister, Indoor air quality, USD, Automation, Sustainability, Energy recovery ventilation, Energy Recovery, Air conditioning, Commercial, Panasonic, Internet, Control, YOY, Allergen, Free, Carbon, Carrier Global, Nature, HRV, ERV, Atmosphere, Mitsubishi Electric, Environment, Pharmaceutical industry, Geography, Ventilation, Heat

The rising demand for heat and energy recovery ventilation systems due to awareness of indoor air quality drives market growth.

Key Points: 
  • The rising demand for heat and energy recovery ventilation systems due to awareness of indoor air quality drives market growth.
  • The integration of heat and energy recovery ventilation systems with smart building technologies and the Internet of Things is an emerging market trend.
  • Ventilation Units and Components: Heat recovery ventilation (HRV) and energy recovery ventilation (ERV) systems comprise various components essential for their efficient operation.
  • Air Filtration and Indoor Air Quality: The inclusion of air filtration mechanisms within ventilation systems is vital for improving indoor air quality.

Public advisory - Sabril (vigabatrin) 500 mg sachets and tablets found to contain trace amounts of another drug

Retrieved on: 
Thursday, November 9, 2023
Health Canada, Seizure, Risk, Tablet, Tic, Allergy, Patient, Agitation, Child, Spasm, Throat, Mouth, Aggression, Dyskinesia, Psychosis, Pharmacy, Pharmaceutical industry, Nursing, Dietary supplement, Medical device, Vigabatrin

Further to the advisory below, in discussion with Health Canada, Lundbeck Canada Inc. is releasing one lot of Sabril (vigabatrin) 500 mg tablets on the Canadian market found to contain trace amounts of another prescription drug, tiapride.

Key Points: 
  • Further to the advisory below, in discussion with Health Canada, Lundbeck Canada Inc. is releasing one lot of Sabril (vigabatrin) 500 mg tablets on the Canadian market found to contain trace amounts of another prescription drug, tiapride.
  • To help mitigate the ongoing shortage, Health Canada is working with stakeholders to monitor the supply of sachets and tablets.
  • Further to the advisory below, in discussion with Health Canada, Lundbeck Canada Inc. is releasing an additional lot Sabril (vigabatrin) 500 mg in sachet format on the Canadian market found to contain trace amounts of another prescription drug, tiapride.
  • Original Advisory – August 18, 2023:
    Lundbeck Canada Inc. has informed Health Canada that two lots of Sabril (vigabatrin) 500 mg powder for oral solution, in sachet format, were found to contain trace amounts of another prescription drug, tiapride.

Emalex Biosciences Releases Results of 12-Month Open-Label Extension Study for Tourette Syndrome Candidate

Retrieved on: 
Thursday, October 5, 2023
Health, Other Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Paragon, Weight gain, Disease, Antipsychotic, Tic, Anxiety, Pediatrics, Mortality, Safety, Vital signs, Somnolence, Effectiveness, Insomnia, International Congress on Tuberculosis, Tourette syndrome, Ars, Patient, Pharmaceutical industry, MD

An open-label extension study of 121 pediatric patients with Tourette syndrome evaluated the safety profile of the investigational drug ecopipam for up to 12-months of treatment.

Key Points: 
  • An open-label extension study of 121 pediatric patients with Tourette syndrome evaluated the safety profile of the investigational drug ecopipam for up to 12-months of treatment.
  • No new safety concerns were identified based on an evaluation of adverse events, physical exams, vital signs, laboratory results and safety scales, according to Emalex Biosciences.
  • Ecopipam is the lead candidate for Emalex Biosciences, a clinical-stage biopharmaceutical company founded by Paragon Biosciences.
  • The 12-month data supports the continued development of ecopipam as a first-in-class novel therapy for children and adolescents with Tourette syndrome,” said Emalex Biosciences Chief Medical Officer Frederick Munschauer, MD.

Machine learning algorithm applied in classifying tic from non-tic movements

Retrieved on: 
Sunday, August 27, 2023
Becker, Tic, University, Classification, Disease, Random forest, Movement, Data, Patient, Machine learning, Parkinson's disease, Neurology, International Congress on Tuberculosis, Medical imaging, Video game

COPENHAGEN, Denmark, Aug. 27, 2023 /PRNewswire-PRWeb/ -- Machine learning is a promising tool for detecting and distinguishing tics from extra movements, according to a study released today at the International Congress of Parkinson's Disease and Movement Disorders® in Copenhagen, Denmark.

Key Points: 
  • With machine learning technology, researchers could potentially reduce time spent analyzing video recordings of people with tic disorders.
  • The study by Becker and colleagues used a dataset of 63 videos of people with tic disorders to train a Random Forest classifier to identify tic movements.
  • Various predictable features were combined into a single detection tic score and trained using videos from both people with tic disorders and healthy controls.
  • This study applies machine learning to train an algorithm that classifies tics from non-tic extra movements and measures several parameters detailing the temporal distribution of tics, ultimately combining these into a single tic detection score.

Public advisory - Sabril (vigabatrin) 500 mg sachets found to contain trace amounts of another drug

Retrieved on: 
Friday, August 18, 2023
Seizure, Psychosis, Allergy, Tic, Spasm, Aggression, Teva Canada Ltd v Pfizer Canada Inc, Patient, Risk, Child, Dyskinesia, Throat, Health Canada, Agitation, Mouth, Dietary supplement, Pharmaceutical industry, Nursing, Medical device, Vigabatrin

Lundbeck Canada Inc. has informed Health Canada that two lots of Sabril (vigabatrin) 500 mg powder for oral solution, in sachet format, were found to contain trace amounts of another prescription drug, tiapride.

Key Points: 
  • Lundbeck Canada Inc. has informed Health Canada that two lots of Sabril (vigabatrin) 500 mg powder for oral solution, in sachet format, were found to contain trace amounts of another prescription drug, tiapride.
  • Sabril is a prescription drug used to manage epileptic seizures in adults and children, and for infantile spasms (West Syndrome).
  • Health Canada has determined that the health risk of the trace contamination to patients is low.
  • Sabril therapy should not be interrupted, as this may increase the risk of seizures, which could be life-threatening.

UT Health Science Center San Antonio recognized as Parkinson's Foundation Comprehensive Care Center

Retrieved on: 
Tuesday, August 1, 2023
Workforce, Huntington's disease, Deep brain stimulation, Hallucination, University, Center of excellence, Tic, Parkinson's Foundation, University of Texas System, University of Texas Health Science Center at San Antonio, Senior counsel, DSM-IV codes, Therapy, Health, Parkinson's disease dementia, Quality of life, UT Health San Antonio Cancer Center, Research, Brain, Neurology, Department of Neurology, Xuanwu hospital, Dystonia, Bone, Movement, Teaching hospital, Essential tremor, Pain, Social, DBS, Electrode, Parkinson's disease, Neurosurgery, MD, Patient, SAN, Person-centered therapy, Rush Alzheimer's Disease Center, Long School, Long School of Medicine, Movement disorder, Bleeding, Memory, Skin, Disease, Pharmaceutical industry, Nursing, Veterinary medicine, Dentistry, Central Texas

SAN ANTONIO, Aug. 1, 2023 /PRNewswire-PRWeb/ -- The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has been designated a Parkinson's Foundation Comprehensive Care Center, the first of its kind in the state of Texas.

Key Points: 
  • Advanced multidisciplinary care for Parkinson's disease is available at The University of Texas Health Science Center at San Antonio, which this summer was named a Parkinson's Foundation Comprehensive Care Center.
  • SAN ANTONIO, Aug. 1, 2023 /PRNewswire-PRWeb/ -- The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has been designated a Parkinson's Foundation Comprehensive Care Center, the first of its kind in the state of Texas.
  • The UT Health San Antonio Movement Disorders Center is also recognized as a Huntington's Disease Center of Excellence and provides comprehensive care for patients with Huntington's disease.
  • The University of Texas Health Science Center at San Antonio (UT Health San Antonio), a primary driver for San Antonio's $44.1 billion health care and biosciences sector, is the largest academic research institution in South Texas with an annual research portfolio of more than $360 million.

Noema Pharma Appoints Ilise Lombardo, M.D., as Chief Executive Officer

Retrieved on: 
Wednesday, June 21, 2023
Columbia University, Seizure, Yale University, Tourette syndrome, Stuttering, University, Therapy, Central nervous system, Tic, Culture, Sofinnova, Physician, Trigeminal neuralgia, INVU (album), USD, CNS, TS, Axovant Sciences, Science, Pain, TSC, Columbia University Vagelos College of Physicians and Surgeons, Polaris Partners, Patient, Arvell Jones, Brown University, Surgeon, Faculty, Knowledge, Growth, Columbia University College of Dental Medicine, COFD, Psychiatry, Pfizer, Pharmaceutical industry, European, Noema

BASEL, Switzerland, June 21, 2023 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, today announced the appointment of Ilise Lombardo, M.D., as Chief Executive Officer of the Company.

Key Points: 
  • BASEL, Switzerland, June 21, 2023 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, today announced the appointment of Ilise Lombardo, M.D., as Chief Executive Officer of the Company.
  • “We are very excited that Ilise will be stepping into the CEO role at Noema Pharma.
  • Ilise has the expertise and experience to lead Noema as the Company enters its next phase of growth,” said Jeffrey Jonas, M.D., Chairman of Noema Pharma’s Board of Directors.
  • “I am thrilled to assume this leadership position with Noema Pharma at such a critical phase in the Company’s growth,” said Dr. Lombardo.

Genius Brands and Andamiro USA to Release the First Ever “Shaq’s Garage” Arcade Game This Summer Nationwide

Retrieved on: 
Wednesday, May 24, 2023
Maniscalco, Pluto TV, Tic, Life, Garage, TIC, Genius Brands, SVP, Family, News, Amusement park

BEVERLY HILLS, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Following the recent news of the June 5 premiere of Kartoon Channel’s “Shaq’s Garage,” starring and executive produced by the legendary Shaquille O’Neal, on Pluto TV, Genius Brands International, Inc. (Nasdaq: GNUS) and Andamiro USA, announced today the summer release of an exclusive basketball-themed arcade game, TIC SHAQ TOE.

Key Points: 
  • (Nasdaq: GNUS) and Andamiro USA , announced today the summer release of an exclusive basketball-themed arcade game, TIC SHAQ TOE.
  • Inspired by the upcoming animated action-adventure and comedy series for children, the new attraction will begin rolling out nationwide in late June at arcades, family entertainment centers and amusements parks, among other high-traffic entertainment venues.
  • Andamiro understood our mission and created a fun and engaging arcade game that will no doubt be a hit with kids,” stated Lloyd Mintz, SVP, Global Consumer Products, Genius Brands.
  • From the early stages of development, we knew we wanted to be involved, and are thrilled with the result of our Tic SHAQ Toe arcade game!”